Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Novo Nordisks obesity drug CagriSema disappoints again Novo Nordisk A/S combined GLP1-, amylin- and calcitonin receptor agonist CagriSema has failed to meet the expected 25% weight loss within 68 weeks in the second of four pivotal Phase III trials
Copper, an ancient remedy returning to fight microbial, fungal and viral infections
This detailed guide explains what science currently says, what is unknown, and how mothers can make safe health decisions
Multiple epidemiological studies link elevated IGF-1 levels to increased prostate and colorectal cancer risk
US$ 26.96
US$ 27.40
US$ 20.80
US$ 22.90
US$ 22.15
US$ 25.87
US$ 27.52
US$ 21.80
